145 related articles for article (PubMed ID: 35802566)
1. Reduced CREB3L1 expression in triple negative and luminal a breast cancer cells contributes to enhanced cell migration, anchorage-independent growth and metastasis.
Mellor P; Kendall S; Smith S; Saxena A; Anderson DH
PLoS One; 2022; 17(7):e0271090. PubMed ID: 35802566
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
3. CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
Denard B; Jiang S; Peng Y; Ye J
BMC Cancer; 2018 Aug; 18(1):813. PubMed ID: 30103710
[TBL] [Abstract][Full Text] [Related]
4. CREB3L1 is a metastasis suppressor that represses expression of genes regulating metastasis, invasion, and angiogenesis.
Mellor P; Deibert L; Calvert B; Bonham K; Carlsen SA; Anderson DH
Mol Cell Biol; 2013 Dec; 33(24):4985-95. PubMed ID: 24126059
[TBL] [Abstract][Full Text] [Related]
5. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
Rose M; Schubert C; Dierichs L; Gaisa NT; Heer M; Heidenreich A; Knüchel R; Dahl E
Epigenetics; 2014 Dec; 9(12):1626-40. PubMed ID: 25625847
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol.
Girgert R; Emons G; Gründker C
BMC Cancer; 2014 Dec; 14():935. PubMed ID: 25496649
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel.
Plett R; Mellor P; Kendall S; Hammond SA; Boulet A; Plaza K; Vizeacoumar FS; Vizeacoumar FJ; Anderson DH
Sci Rep; 2022 Sep; 12(1):15663. PubMed ID: 36123435
[TBL] [Abstract][Full Text] [Related]
8. Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1.
Feng YX; Jin DX; Sokol ES; Reinhardt F; Miller DH; Gupta PB
Nat Commun; 2017 Oct; 8(1):1079. PubMed ID: 29057869
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy Controls Metastasis Through Stimulatory Effects on GRP78 and Its Transcription Factor CREB3L1.
Raiter A; Lipovetsky J; Hyman L; Mugami S; Ben-Zur T; Yerushalmi R
Front Oncol; 2020; 10():1500. PubMed ID: 33042795
[TBL] [Abstract][Full Text] [Related]
10. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
12. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
[TBL] [Abstract][Full Text] [Related]
13. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1.
Denard B; Lee C; Ye J
Elife; 2012 Dec; 1():e00090. PubMed ID: 23256041
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
16. Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.
Denard B; Pavia-Jimenez A; Chen W; Williams NS; Naina H; Collins R; Brugarolas J; Ye J
PLoS One; 2015; 10(6):e0129233. PubMed ID: 26110425
[TBL] [Abstract][Full Text] [Related]
17. FGF13 promotes metastasis of triple-negative breast cancer.
Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH
Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002
[TBL] [Abstract][Full Text] [Related]
18. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
19. 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Girgert R; Emons G; Gründker C
Oncol Rep; 2017 Feb; 37(2):1212-1218. PubMed ID: 27959426
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer.
Le UQ; Chen N; Balasenthil S; Lurie E; Yang F; Liu S; Rubin L; Solis Soto LM; Raso MG; Batra H; Sahin AA; Wistuba II; Killary AM
Sci Rep; 2022 Nov; 12(1):19504. PubMed ID: 36376460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
